Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Confo Therapeutics Enters into Collaborative Agreement with Regeneron Pharmaceuticals, Inc

11/30/2021 | 05:00am EST

Confo Therapeutics announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo?s technology platform, which uses conformationally selective VHH antibodies ? ConfoBodies ? to stabilize GPCRs (G protein-coupled receptors) in disease-relevant conformations, will be applied with the goal of enabling the discovery of novel therapeutic antibody drug candidates. The agreement will leverage Confo?s expertise in addressing two GPCR targets for which functional antibodies are needed. Confo will be entitled to an upfront payment, research funding, and potential clinical, regulatory, and commercial payments. Confo?s ConfoBody-based technology platform aims to overcome the limitations of drug discovery on GPCRs, the large and most diverse group of membrane receptors targeted by approximately 30% of all commercialized drugs.


ę S&P Capital IQ 2021
All news about REGENERON PHARMACEUTICALS
12:01pForty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talen..
PR
09:31aFda accepts for review libtayo in combination with chemotherapy for first-line treatmen..
AQ
01/19Regeneron Says US FDA Accepts for Review its Supplemental BLA for Libtayo in Combinatio..
MT
01/19Regeneron Says FDA to Review Libtayo/Chemotherapy Combo in First-Line NSCLC Treatment
DJ
01/19FDA Accepts for Review Libtayo« (cemiplimab-rwlc) in Combination with Chemotherapy for ..
PR
01/19FDA Accepts for Review Libtayo« (cemiplimab-rwlc) in Combination with Chemotherapy for ..
CI
01/19Sanofi, Regeneron Say Dupixent Significantly Reduces Itching in Prurigo Nodularis Patie..
MT
01/19Sanofi-Regeneron's Dermatitis Drug Lowers Itch, Skin Lesions In Late-Stage Trial
MT
01/19Second Positive Phase 3 Dupixent« (dupilumab) Trial Confirms Significant Improvements f..
PR
01/18Morgan Stanley Adjusts Regeneron Pharmaceuticals Price Target to $585 From $617, Mainta..
MT
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 15 515 M - -
Net income 2021 7 967 M - -
Net cash 2021 4 180 M - -
P/E ratio 2021 8,72x
Yield 2021 -
Capitalization 64 237 M 64 237 M -
EV / Sales 2021 3,87x
EV / Sales 2022 4,27x
Nbr of Employees 9 766
Free-Float 81,7%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 614,38 $
Average target price 697,73 $
Spread / Average Target 13,6%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS-2.71%64 627
GILEAD SCIENCES, INC.-4.88%86 640
VERTEX PHARMACEUTICALS5.12%58 692
WUXI APPTEC CO., LTD.-6.39%51 406
BIONTECH SE-37.29%39 044
BEIGENE, LTD.-12.58%24 335